Evidence map›Paper›PMID 32642965›Full record

ArticleAdvances in therapy2020

Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors.

Robert S Epstein, Matti S Aapro, Upal K Basu Roy, Tehseen Salimi, JoAnn Krenitsky, Megan L Leone-Perkins, Cynthia Girman, Courtney Schlusser, Jeffrey Crawford

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 5 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 5 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Efficacy and safety of trilaciclib to prevent chemotherapy-induced myelosuppression in advanced solid tumors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Trial
  7. Trial
  8. First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients WithJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Robert S EpsteinEpstein Health, LLC, Woodcliff Lake, NJ, USA. repstein@epsteinhealth.com.
Matti S AaproClinique de Genolier, Genolier, Switzerland.
Upal K Basu RoyLUNGevity Foundation, Bethesda, MD, USA.
Tehseen SalimiG1 Therapeutics, Inc., Research Triangle Park, NC, USA.
JoAnn KrenitskyEpstein Health, LLC, Woodcliff Lake, NJ, USA.
Megan L Leone-PerkinsHealthiVibe, Corrona, LLC, Arlington, VA, USA.
Cynthia GirmanCERobs Consulting, LLC, Chapel Hill, NC, USA.
Courtney SchlusserUNC Gillings School of Global Public Health, Chapel Hill, NC, USA.
Jeffrey CrawfordDuke University Medical Center, Durham, NC, USA.
Clinique de Genolier · CHDuke Medical Center · USLUNGevity Foundation · USTriangle · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChemotherapy-induced myelosuppression (CIM) is one of the most common dose-limiting complications of cancer treatment, and is associated with a range of debilitating symptoms that can significantly impact patients' quality of life. The purpose of this study was to understand patients' perspectives on how the side effects of CIM are managed in routine clinical practice.

methodsAn online survey was conducted of participants with breast, lung, or colorectal cancer who had received chemotherapy treatment within the past 12 months, and had experienced at least one episode of myelosuppression in the past year. The survey was administered with predominantly close-ended questions, and lay definitions of key terms were provided to aid response selection.

resultsOf 301 participants who completed the online survey, 153 (51%) had breast cancer, 100 (33%) had lung cancer, and 48 (16%) had colorectal cancer. Anemia, neutropenia, lymphopenia, and thrombocytopenia were reported by 61%, 59%, 37%, and 34% of participants, respectively. Most participants (79%) reported having received treatment for CIM, and 64% of participants recalled chemotherapy dose modifications as a result of CIM. Although most participants believed their oncologist was aware of the side effects of CIM, and treated them quickly, 30% of participants felt their oncologists did not understand how uncomfortable they were due to the side effects of CIM. Overall, 88% of participants considered CIM to have a moderate or major impact on their lives.

conclusionThe data highlight that despite the various methods used to address CIM, and the patient-focused approach of oncologists, the real-world impact of CIM on patients is substantial. Improving communication between patients and health care providers may help improve patients' understanding of CIM, and foster shared decision-making in terms of treatment. Additional insights from patients should be obtained to further elucidate the totality of life burden associated with CIM.

Indexed as

AdolescentAdultAgedAged, 80 and overAntineoplastic AgentsBreast NeoplasmsColorectal NeoplasmsDrug-Related Side Effects and Adverse ReactionsFemaleHumansLung NeoplasmsMaleMiddle AgedSurveys and QuestionnairesUnited StatesYoung AdultAntineoplastic AgentsAnemiaChemotherapyMyelosuppressionNeutropeniaOncologyOnline surveyPatient burdenReal-worldSymptom managementThrombocytopenia

Identifiers

PMID32642965
PMCPMC7340862
OpenAlexW3041070518

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.